MRIdian System Limits Early Toxicity for Prostate Cancer Without Implanted Markers (Imaging Technology News)

MRIdian System Limits Early Toxicity for Prostate Cancer Without Implanted Markers

UF startup ViewRay Inc., a leading medical technology company that provides groundbreaking MRI-guided radiation therapy, announced the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer. This robust study of clinician and patient-reported outcomes demonstrated zero CTCAE v4 grade 3 or higher gastrointestinal (GI) and genitourinary (GU) toxicity and even lower incidence of grade 2 toxicity than investigators hypothesized. It is also one of the first prospective clinical trials to study stereotactic body radiation therapy (SBRT) in a mix of intermediate- and high-risk prostate cancer patients, a challenging patient population to treat.

Learn more about MRIdian System Limits Early Toxicity for Prostate Cancer Without Implanted Markers.
X